Skip to main content
. 2022 Dec 9;14(24):6062. doi: 10.3390/cancers14246062

Figure 2.

Figure 2

The β-catenin-TCF4 pathway is activated in patients with HBL and increases expression of CEGRs/ALCDs-containing genes. (A) Co-IP studies. Input: levels of β-catenin, TCF4, p300 in protein extracts used for IP. Bottom images show results of Co-IP studies. (B) Pull-down assay with a DNA oligomer containing a conserved TCF4 binding site identified in all studied CEGRs/ALCDs. (C) ChIP assay with CEGRs/ALCDs of five oncogenes. B: beads, in: input. Chromatin solutions from two HBL patients expressing only WT β-catenin were used. (D,E) QRT-PCR analyses shows mRNA levels of HACE1 (p = 0.0006), NRF2 (p = 0.1985), TNFRSF19 (p = 0.0407), HMGA2 (p = 0.0002), Thy1 (p = 0.2022), AFP (p = 0.2586), TCF4 (p = 0.2649), and REG3A (p = 0.1503) (unpaired t-tests). The uncropped Western blots have been shown in Figure S9.